Table 1 Comparison of AR:ER ratio to clinical and pathologic variables
From: Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
|  | AR:ER <2 | AR:ER ≥2 | Chi-square | ||
|---|---|---|---|---|---|
Variable | n | % | n | % | P value |
Age <50 | 170 | 7.6 | 22 | 13.6 | 0.34 |
Tumor size >2Â cm | 170 | 42.9 | 22 | 59.1 | 0.15 |
Tumor grade 2 + 3 | 169 | 91.1 | 22 | 100 | 0.15 |
Lymph node-positive | 133 | 54.1 | 14 | 85.7 | 0.02 |
Failed tamoxifen treatment | 170 | 20.6 | 22 | 59.1 | <0.0001 |
AR-positive | 170 | 88.2 | 22 | 100 | 0.09 |
Progesterone receptor-positive | 123 | 83.7 | 8 | 75.0 | 0.52 |
MIB-1 ≥21.3 | 168 | 53.0 | 21 | 23.8 | 0.01 |
Mitotic index number >4 | 165 | 50.3 | 22 | 45.5 | 0.67 |
erbB2 >30% | 149 | 8.1 | 20 | 20.0 | 0.09 |
EGFR-positive | 147 | 16.3 | 19 | 10.5 | 0.51 |